MIP Discovery
Louisa Williamson MSc MBiomed MIBMS is an experienced professional who has held various roles in the medical and healthcare industry. With a strong background in biomedical sciences and medical microbiology, Louisa has worked in both the NHS and private sector. Currently serving as the Global Head of Product Management & Customer Service at MIP Discovery, Louisa has excelled in roles such as Product Manager Clinical Microbiology, Product Manager Lab Efficiency, and Specialist Biomedical Scientist. Their educational background includes a Master of Science in Biomedical Science and Medical Microbiology, as well as a Specialist Diploma in Medical Microbiology and Bacteriology.
This person is not in any teams
MIP Discovery
Our proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. NanoMIPS are, as the name suggests, nanostructured polymer particles typically containing a single binding site for their target. They can also be fused to solid substrates, such as sensor surfaces, if required. The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field based testing. As they are synthetic polymers, MIPs can withstand harsh chemical environments such as extremes of pH, seawater, or high concentrations of organic solvents. In addition, MIPs have a very long shelf life at room temperature which makes them ideal when the cold chain cannot be guaranteed. MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors. Using our proprietary nanoMIP design and development process, MIP Diagnostics can provide a proven nanoMIP typically within 4-6 weeks of receiving the target.